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Cells run on carbohydrates. Glycans, sequences of carbohydrates conjugated to proteins and
lipids, are arguably themost abundant and structurally diverse class of molecules in nature. Recent
advances in glycomics reveal the scope and scale of their functional roles and their impact on
human disease.By analogy to the genome, transcriptome,
or proteome, the ‘‘glycome’’ is the
complete set of glycans and glycoconju-
gates that are made by a cell or organism
under specific conditions. Therefore,
‘‘glycomics’’ refers to studies that attempt
to define or quantify the glycome of a cell,
tissue, or organism (Bertozzi and Sasise-
kharan, 2009). In eukaryotes, protein
glycosylation generally involves the cova-
lent attachment of glycans to serine,
threonine, or asparagine residues. Glyco-
proteins occur in all cellular compart-
ments. Glycans are also attached to
lipids, often ceramide, which is comprised
of sphingosine, a hydrocarbon amino
alcohol and a fatty acid. Complex glycans
are mainly attached to secreted or cell
surface proteins, and they do not cycle
on and off of the polypeptide. In contrast,
the monosaccharide O-linked N-acetyl-
glucosamine (O-GlcNAc) cycles rapidly
on serine or threonine residues of many
nuclear and cytoplasmic proteins. Identi-
fying the number, structure, and function
of glycans in cellular biology is a daunting
task but one that has been made easier in
recent years by advances in technology
and by our growing appreciation of how
integral glycans are to biology (Varki
et al., 2009).
The scope of the glycomics challenge is
immense. The covalent addition of
glycans to proteins and lipids represents
not only the most abundant posttransla-
tional modification (PTM), but also by far
the most structurally diverse. Although it
is commonly stated that more than 50%
of all polypeptides are covalently modified
by glycans (Apweiler et al., 1999), even
this estimate is far too low because it fails
to include that myriad nuclear and
cytoplasmic proteins are modified by672 Cell 143, November 24, 2010 ª2010 ElseO-GlcNAc (Hart et al., 2007). Even though
the generic term ‘‘glycosylation’’ is often
used to categorize and lump all glycan
modifications of proteins into one bin,
side by side with other posttranslational
modifications such as phosphorylation,
acetylation, ubiquitination, or methylation,
such a view is not only inaccurate, but
also is completely misleading. If one only
considers the linkage of the first glycan
to the polypeptide in both prokaryotic
and eukaryotic organisms, there are at
least 13 different monosaccharides and
8 different amino acids involved in glyco-
protein linkages, with a total of at least
41 different chemical bonds known to be
linking the glycan to the protein (Spiro,
2002). Importantly, each one of these
unique glycan:protein linkages is surely
as different in both structure and function
as protein methylation is from acetylation.
Of course, this modification is not only
about a single linkage. When structural
diversity of the additional oligosaccharide
branches of glycans and the added diver-
sity of complex terminal saccharides on
glycans, such as fucose or sialic acids
(about 50 different sialic acids are known
[Schauer, 2009]), are taken into account,
the molecular diversity and varied func-
tions of protein-bound glycans rapidly
increase exponentially. Just the ‘‘sia-
lome’’ (Cohen and Varki, 2010) rivals or
exceeds many other posttranslational
modifications in abundance and struc-
tural/functional diversity. In addition,
chemical modifications, such as phos-
phorylation, sulfation, and acetylation,
increase the glycan structural/functional
diversity even more. Thus, categorizing
glycosylation as a single type of post-
translational modification is neither useful
nor at all reflective of reality.vier Inc.Dynamic Structural Complexity
Underlies Glycan Functions
Glycoconjugates provide dynamic struc-
tural diversity to proteins and lipids that
is responsive to cellular phenotype, to
metabolic state, and to the developmental
stage of cells. Complex glycans play crit-
ical roles in intercellular and intracellular
processes, which are fundamentally
important to the development of multicel-
lularity (Figure 1). Unlike nucleic acids and
proteins, glycan structures are not hard-
wired into the genome, depending upon
a template for their synthesis. Rather,
the glycan structures that end up on
a polypeptide or lipid result from the
concerted actions of highly specific gly-
cosyltransferases (Lairson et al., 2008),
which in turn are dependent upon the
concentrations and localization of high-
energy nucleotide sugar donors, such as
UDP-N-acetylglucosamine, the endpoint
of the hexosamine biosynthetic pathway.
Therefore, the glycoforms of a glycopro-
tein depend upon many factors directly
tied to both gene expression and cellular
metabolism.
There are at-least 250 glycosyltrans-
ferases in the human genome, and it has
been estimated that about 2% of the
human genome encodes proteins
involved in glycan biosynthesis, degrada-
tion, or transport (Schachter and Freeze,
2009). Biosynthesis of the nucleotide
sugar donors is directly regulated by nu-
cleic acid, glucose, and energy metabo-
lism, and the compartmentalization of
these nucleotide sugar donors is highly
regulated by specific transporters. Protein
glycosylation is therefore controlled by
rates of polypeptide translation and
protein folding, localization of and compe-
tition between glycosyltransferases,
Figure 1. Glycans Permeate Cellular Biology
Complex glycans at the cell surface are targets of microbes and viruses, regulate cell adhesion and devel-
opment, influence metastasis of cancer cells, and regulate myriad receptor:ligand interactions. Glycans
within the secretory pathway regulate protein quality control, turnover, and trafficking of molecules to
organelles. Nucleocytoplasmic O-linked N-acetylglucosamine (O-GlcNAc) has extensive crosstalk with
phosphorylation to regulate signaling, cytoskeletal functions, and gene expression in response to nutrients
and stress.cellular concentration and localization of
nucleotide sugars, the localization of
glycosidases, and membrane trafficking.
Thus, individual glycosylation sites on the
same polypeptide can contain different
glycan structures that reflect both the
type and status of the cell in which they
are synthesized. For example, the glyco-
forms of the membrane protein Thy-1 are
very different in lymphocytes than they
are in brain, despite having the same poly-
peptide sequence (Rudd and Dwek,
1997). Conversely, even small changes in
polypeptide sequence or structure will
alter the types of glycan structures
attached to a polypeptide. For example,
histocompatibility antigen polypeptides
with more than 90% sequence homology
contain different N-linked glycan profiles
at individual sites, reflective of their
allelic type, even when they are synthe-
sized within the same cells (Swiedler
et al., 1985). Thus, site-specific protein
glycosylation is highly regulated bygene expression of glycan-processing
enzymes, by polypeptide structure at all
levels, and by cellular metabolism.
Technology of Glycomics
A detailed understanding of cellular
processes will require a detailed appreci-
ation of the glycans modulating proteins
and pathways. Although this ultimate
goal of glycomics is laudable, we are
a very long way from having the tech-
nology to completely characterize the gly-
come of even a simple cell or tissue. Not
only is the glycome much more complex
than the genome, transcriptome, or pro-
teome, as noted above, it is also much
more dynamic, varying considerably not
only with cell type, but also with the
developmental stage and metabolic state
of a cell. Even very conservative esti-
mates indicate that there are well over
a million different glycan structures in
a mammalian cell’s glycome. However,
upon considering ‘‘functional glycomics,’’Cell 143, Nit is estimated that the binding sites of
glycan-binding proteins (GBPs), such as
antibodies, lectins, receptors, toxins, mi-
crobial adhesions, or enzymes (Figure 1),
can accommodate only up to two to six
monosaccharides within a glycan struc-
ture (Cummings, 2009). Therefore, the
number of specific glycan substructures
that bind to biologically important GBPs
in a cell may be fewer than 10,000,
a number that is within the realm of
current analytical and, if targeted, chemi-
cal or enzymatic synthetic capabilities.
Until recently, the lack of tools and the
inherent complexity of glycans have
been major barriers preventing most biol-
ogists from embracing the importance of
glycans in biology. Recent technological
advances have significantly lowered these
barriers. Indeed, the tools of glycomics
and the subfields of glycoproteomics, gly-
colipidomics, and proteoglycomics have
all progressed substantially in recent
years (Krishnamoorthy and Mahal, 2009;
Laremore et al., 2010). Major technolog-
ical advances, many of which are shared
with proteomics, have recently allowed
semiquantitative profiling of glycans and
glycoproteins (Krishnamoorthy and
Mahal, 2009; Vanderschaeghe et al.,
2010). Some of these advances are the
result of the National Institute of General
Medical Science’s (NIGMS) support of
the Consortium for Functional Glycomics
(CFG), which has served to focus and
assist more than 500 researchers on
issues related to glycomics (Paulson
et al., 2006; Raman et al., 2006).
Kobata and colleagues were among the
first to profile N-glycans, well before the
current concepts of glycomics were
conceived. Despite the lack of many
modern methods, their pioneering work
was characterized by a high level of rigor
in defining the arrays of N-glycan struc-
tures present in cells and tissues and on
specific proteins (Endo, 2010). Currently,
a wide variety of high-resolution and
highly sensitive methods are available,
including capillary electrophoresis (CE),
high-performance liquid chromatography
(HPLC), and lectin microarrays.
Glycans are often profiled after their
release from polypeptides, which results in
the loss of any information about proteins
and sites to which they were attached.
Even though it is much more difficult, it is
also much preferable to performovember 24, 2010 ª2010 Elsevier Inc. 673
glycopeptide profiling (glycoproteomics) to
first identify attachment sites prior to
detailed profiling or structural analysis of
the glycans present on a polypeptide. The
ultimate goal of glycoproteomics, which is
todefineall of themolecular species (glyco-
forms) of glycoproteins in a cell or tissue,
has not yet been realized for any glycopro-
tein with more than one glycan attachment
site. N-glycans are generally released from
proteins by peptide-N-glycosidase F
(PNGase F), which cleaves most, but not
all, N-glycans. Unfortunately, no such
broadly specific enzyme exists for
O-glycans, which are generally released
by chemical methods, such as alkali-
induced b elimination, or by hydrazinolysis.
However, for relatively pure glycoproteins,
so called ‘‘top-down’’ mass spectrometric
methods,whichdo not involveprior release
of the glycans,may eventually prove useful,
as instrumentation and methods improve
(Reid et al., 2002).
Due to the small sample sizes involved,
most CE or HPLC separation methods
require chemical modification of released
glycans with fluorescent compounds. CE
and HPLC methods provide high-resolu-
tion separation of glycans, and when
combined with laser-induced fluorescent
detection (LIF), tagged glycans can be de-
tected in the low femtomole range. High
pH anion-exchange chromatography
(HPAEC) with pulsed-amperometric
detection separates glycans with high
resolution and detects them with high
sensitivity without chemical modification,
but the high alkalinity employed can be
problematic for some labile structures.
Lectins, which are defined as carbohy-
drate-binding proteins that are neither
antibodies nor enzymes, have a wide
range of glycan binding specificities, suit-
able for partial characterization of a gly-
come. Lectin microarrays use methods
and equipment similar to that employed
for nucleic acid arrays. Given the large
number of different lectins available, lectin
microarrays can provide information
about the glycome in a high-throughput
fashion, which is particularly useful in
profiling glycans produced by infectious
organisms (Hsu et al., 2006). In the future,
it is highly likely that glycomics will play
a central role in combating infectious
disease. However, many technical issues
remain to be resolved, such as standard-
ization required for clinical use, the674 Cell 143, November 24, 2010 ª2010 Elsedevelopment of purified recombinant lec-
tins, and better definition of the specific-
ities of many lectins (Gupta et al., 2010).
Both matrix-assisted laser desorption
ionization (MALDI) and electrospray
mass spectrometry have played a key
role in glycan profiling and in glycoproteo-
mics (An et al., 2009; North et al., 2010;
Zaia, 2010). For biomarker discovery,
affinity enrichment approaches, based
upon chemical modification and solid-
phase extraction of N-linked glycopro-
teins, have proven useful in profiling
N-linked glycoprotein sites from serum-
or even from paraffin-embedded tissues
(Tian et al., 2009). Recently, using lectin
binding combined with advanced mass
spectrometric methods, thousands of
N-glycan attachment sites have been
mapped, a prerequisite for understanding
their functions (Zielinska et al., 2010).
Given the structural diversity of
glycans, all of these glycomic approaches
generate vast amounts of data. Glycan bi-
oinformatics has made great strides
within recent years with major efforts
from several laboratories (Aoki-Kinoshita,
2008). At least four major publicly
available carbohydrate databases (Glyco-
sciences.de, KEGG GLYCAN, Euro-
carbDB, and CFG) are now maintained,
and efforts to structure them in a uniform
format have been in progress for quite
some time. In addition, the Carbohy-
drate-Active EnZyme database (CAZy)
has played a key role in providing a global
understanding of carbohydrate active
enzymes, documenting their evolutionary
relationships, providing a framework for
elucidating common mechanisms, and
establishing the relationship between gly-
cogenomics and glycomes expressed by
cells (Cantarel et al., 2009). Moreover,
recent advances in bioinformatic analysis
tools for complex glycomic mass spec-
trometry data sets have allowed complex
data to be presented in formats useful to
nonexperts in all fields of biology (Ceroni
et al., 2008; Goldberg et al., 2005).
Perhaps one of the most important
contributions to the field of functional
glycomics has been the development of
well-defined glycan microarrays, which
currently display more than 500 different
glycan structures (Smith et al., 2010).
The NIGMS-supported Consortium for
Functional Glycomics (CFG) has gener-
ated and made publicly availablevier Inc.custom-made DNA microarrays that
represent glycosyltransferases and
glycan-binding proteins. The CFG also
has developed databases that present
phenotypic and biochemical data on gly-
cosyltransferase knockout mice. Even
though knocking out a single glycosyl-
transferase gene often affects hundreds
of glycoconjugates and myriad biological
processes, these mutant mice have
proven valuable in revealing the funda-
mental biological importance of glycans.
The microarrays and the databases
producedby theCFGmember community
at large are publically available on theCFG
website (http://www.functionalglycomics.
org) and have resulted in a profound
increase in our understanding of the
binding specificities of GBPs, including
lectins key to inflammation and immunity,
and on infectious microbes or viruses.
However, a major barrier preventing
glycan biology from being incorporated
more into themainstream is the continued
failure by thecommunity to adopt auniver-
sally standard glycan structural format
and database that are easily accessed
worldwide.Most importantly, glycandata-
bases must eventually be incorporated
into standard interactive databases that
are supported by public agencies (such
as NCBI or EMBL) before glycan biology
can be fully integrated into the wider
research community.
From Glycomics to Biology
Glycans are directly involved in almost
every biological process and certainly
play a major role in nearly every human
disease (Figure 1). Genetic studies in
tissue culture cells indicate that specific
complex glycan structures are generally
not essential to a cell growing in culture,
indicating that most of the functions of
complex glycans are at the multicellular
level. In contrast, the cycling monosac-
charide, O-GlcNAc, on nuclear and cyto-
plasmic proteins, is essential even at the
single cell level in mammals (Hart et al.,
2007).
The critical roles of glycans inmammals
are now well established not only by the
dearth of mutations in glycan biosynthetic
enzymes that survive development, but
also by the severe phenotypes generated
when such mutations are not lethal.
These severe phenotypes are clearly illus-
trated by the congenital disorders of
Figure 2. Glycomic Complexity Reflects Cellular Complexity
Given that glycan structures are regulated by metabolism and glyco-enzyme expression and glycans
modify both proteins and lipids, functional glycomics also requires the tools of genomics, proteomics, lip-
idomics, and metabolomics (modified after Packer et al., 2008).glycosylation (CDGs) (Schachter and
Freeze, 2009), which are associated with
severe mental and developmental abnor-
malities. Also, the severe muscular
dystrophy that results from defective
O-glycosylation of a-dystroglycan (Yosh-
ida-Moriguchi et al., 2010) further
illustrates how a mutation in a glycan
biosynthetic enzyme results in a devas-
tating disease. The interplay between
O-GlcNAcylation and phosphorylation on
nuclear and cytoplasmic proteins plays
a key role in the etiology of diabetes,
neurodegenerative disease, and cancer
(Hart et al., 2007; Zeidan and Hart, 2010).
It has long been appreciated that alter-
ations in cell surface glycans contribute to
the metastatic and neoplastic properties
of tumor cells (Taniguchi, 2008). The func-
tions of many receptors are modulated by
their glycans, such as modulation of
Notch receptors by the action of specific
glycosyltransferases (Moloney et al.,
2000), which regulate Notch’s activation
by its ligands, affecting many develop-
mental events. Selectins, which specifi-
cally bind to a subset of fucosylated and
sialylated glycans, play a critical role in
leukocyte homing to sites of inflamma-
tion. Indeed, a selectin inhibitor is
currently in phase two clinical trials for
vaso-occlusive sickle cell disease (Chang
et al., 2010). Siglecs, which are a family of
cell surface sialic acid-binding lectins,
play a fundamental role in regulating
lymphocyte functions and activation.
Recent studies on galectins, a family of
b-galactoside-binding lectins, have
shown that they play a critical role in theorganization of receptors on the cell
surface and play important roles in immu-
nity, infections, development, and inflam-
mation (Lajoie et al., 2009). Proteoglycans
and glycosaminoglycans play a key role in
the regulation of growth factors, in micro-
bial binding, in tissuemorphogenesis, and
in the etiology of cardiovascular disease.
Proteoglycans are perhaps the most
complicated and information-rich mole-
cules in biology, and progress in proteo-
glycomics has begun to accelerate
(Ly et al., 2010). Nearly all microbes and
viruses that infect humans bind to cells
by attaching to specific cell surface
glycans. Glycomics and glycan arrays
will have a substantial impact upon future
research toward both diagnosing and
preventing infectious disease.
Someof themost important drugson the
market are already the result of glycomics.
The anti-flu virus drugs Relenza and Tami-
flu are structural analogs of sialic acids that
inhibit the flu virus neuraminidase and the
transmission of the virus. Natural heparin,
a sulfated glycosaminoglycan, and chemi-
cally defined synthetic heparin oligosac-
charides have long been widely used in
the clinic as anticoagulants and for many
other clinical uses. Hyaluronic acid, a non-
sulfated glycosaminoglycan, is used in the
treatment of arthritis. Many recombinant
pharmaceuticals, including therapeutic
monoclonal antibodies, are glycoproteins,
and their specific glycoforms are key to
their bioactivity and half lives in circulation
and to their possible induction of delete-
rious immune responses when they do
not contain the correct glycans. Given thisCell 143, Nlandscape, the pharmaceutical industry
and the US Food and Drug Administration
are rapidly realizing the critical importance,
in terms of both bioactivity and safety, of
carefully defining the glycoforms of any
therapeutics derived from glycoconju-
gates.
Glycoproteomics, Glycolipidomics,
and Biomarkers
Clinical cancer diagnostic markers are
often glycoproteins, but most current
diagnostic tests only measure the expres-
sion of the polypeptide. Clearly, given the
long known alterations in glycans associ-
ated with cancer, it is highly likely that
cancermarkers that detect specific glyco-
forms of a protein will have much higher
sensitivity and specificity for early
detection of cancer (Packer et al., 2008;
Taniguchi, 2008). Thus, the convergence
of glycomics and glycoproteomics is key
to thediscovery of biomarkers for the early
detection of cancer (Taylor et al., 2009).
Recently, the Food and Drug Administra-
tion has approved fucosylated a-fetopro-
tein as a diagnostic marker of primary
hepatocarcinoma. In addition, fucosy-
lated haptoglobin may be a much better
marker of pancreatic cancer than simply
monitoring the expression of the hapto-
globin polypeptide. Indeed, The National
Cancer Institute has begun an initiative to
discover, develop, and clinically validate
glycan biomarkers for cancer (http://
glycomics.cancer.gov/). System biology
analyses of the glycome to identify
biomarkers of human disease will, by
necessity, also employ many of the same
methods used by genomics, proteomics,
metabolomics, and lipidomics (Figure 2)
(Packer et al., 2008). Due to the critical
roles of glycans in cardiovascular disease
and lung disease and in the functions of
blood cells, the National Heart Lung and
Blood Institute (NHLBI) has recognized
an acute need to train more researchers
in the area of glycosciences by creating
a ‘‘Program of Excellence in Glycoscien-
ces,’’ which will not only support collabo-
rative research, but will also provide
hands-on laboratory training in the
methods of glycosciences to fellows.
Thus, though our knowledge about the
biology of glycans and glycomics
continues to lag behind more mainstream
fields of genomics and proteomics, tech-
nological advances in glycomics in theovember 24, 2010 ª2010 Elsevier Inc. 675
last 5 years have begun to accelerate the
integration of glycobiology into the other
major fields of biomedical research. A
complete mechanistic understanding of
the etiology of almost any disease will
depend upon the elucidation of the func-
tions of all posttranslational modifications
but will especially depend upon our
understanding the many roles of glycans,
the most abundant and structurally
diverse type of posttranslational modifi-
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